SCHEMBL643245

SCHEMBL643245

[CH2]C1CCC(C(c2ccccc2)N(C)C)CC1

nearest known ligand 0.38

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.38
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
OPRM1 P35372 5/20 0.35
SLC6A4 P31645 1/20 0.35
KDR P35968 1/20 0.35
SLC6A3 Q01959 1/20 0.35
HTR2A P28223 2/20 0.34
HRH1 P35367 2/20 0.34
TDP1 Q9NUW8 1/20 0.33
GAA P10253 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
EPHX2 P34913 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13903208 0.83 GAA (0.47) IDO1OPRM1SLC6A4KDRSLC6A3
SCHEMBL17900515 0.83 GAA (0.47) IDO1OPRM1SLC6A4KDRSLC6A3
SCHEMBL1327227 0.82 OPRM1 (0.41) IDO1KDM4EALDH1A1OPRM1SLC6A4
SCHEMBL493016 0.82 OPRL1 (0.42) IDO1KDM4EALDH1A1OPRM1SLC6A4
SCHEMBL6258817 0.81 IDO1 (0.49) IDO1OPRM1SLC6A4KDRSLC6A3
SCHEMBL2310032 0.80 CARM1 (0.39) IDO1ALDH1A1GAAL3MBTL1EPHX2
SCHEMBL645073 0.80 KDM4E (0.36) IDO1KDM4EALDH1A1OPRM1SLC6A4
Hydrochloric Acid SCHEMBL1328025 0.79 CARM1 (0.38) IDO1ALDH1A1GAAL3MBTL1EPHX2
SCHEMBL493239 0.79 OPRD1 (0.45) SLC6A4SLC6A3
SCHEMBL1326984 0.78 KDM4E (0.40) IDO1KDM4EALDH1A1OPRM1SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119633-B2 N-{2-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-2-oxo-ethoxy]-ethyl}-N-ethyl-4-methoxy-2,3,6-trimethyl-phenylsulfonamide; condensing the N-carboxyalkyl phenylsulfonamide with the substituted piperidine; bradykinin receptor antagonists; analgesics; antidiabetics; angiogenesis inhibitors; rheumatic diseases GRUENENTHAL GMBH (DE) 2012-02-21 US disclosed